QNTMQuantum Biopharma Ltd. Class B Subordinate Voting Shares — stock analysis & sentiment

At $3.45, the stock trades near the low end of a 52-week range that runs from $2.07 to $31.914. That range is unusually wide — the high is roughly nine times the low — and the current price sits closer to the floor than the ceiling, so the past year has covered a very large span rather than a narrow band. With a market capitalization of about $22 million, this is a micro-cap name, and price moves of that magnitude are typical of companies at that size.

The profitability figures show a business that is not currently earning. Reported profit margin is zero, and the forward price-to-earnings ratio of -0.44 is negative, which is what happens when expected earnings are below zero rather than a conventional earnings multiple. Price-to-book stands at roughly 33.8, meaning the market values the shares well above the accounting value of the company's net assets — a pattern common where value rests on development-stage assets rather than current results. Beta of 0.43 places historical movement at well under the market's, so day-to-day direction has been driven more by company-specific developments than by broad index moves.

Recent news flow is entirely company-specific rather than sector-wide. The most recent items, from late July 2026, cover the announced intention to settle debt and the subsequent closing of that debt settlement, following a private placement whose initial tranche closed in March 2026. The remainder of the flow consists of a series of corporate updates issued in March, April, and June 2026. Taken together, the headlines center on financing and balance-sheet housekeeping alongside routine company communications, with no items in this set tied to wider healthcare or biotechnology industry events.